Key Quantitative Figures

Standalone Financial Results (Q1 FY27 ended June 30, 2026):

  • Revenue from operations: ₹125.11 million
  • Other income: ₹12.25 million
  • Total income: ₹137.36 million
  • Total expenses: ₹135.21 million
  • Profit before tax: ₹2.15 million
  • Total tax expense: ₹(0.90) million (credit)
  • Profit after tax: ₹3.05 million
  • Basic/Diluted EPS: ₹0.15
  • Paid-up equity share capital: ₹103.48 million (Face value ₹5 per share)

Comparative Standalone Figures:

  • Q4 FY26 (Mar 31, 2026): PAT ₹42.55 million, EPS ₹2.06
  • Q1 FY26 (Jun 30, 2025): PAT ₹39.52 million, EPS ₹1.90
  • FY26 (Mar 31, 2026): PAT ₹95.91 million, EPS ₹4.63

Consolidated Financial Results (Q1 FY27 ended June 30, 2026):

  • Revenue from operations: ₹853.47 million
  • Other income: ₹64.23 million
  • Total income: ₹917.70 million
  • Total expenses: ₹1,104.44 million
  • Loss before tax: ₹(197.10) million
  • Total tax expense: ₹(25.74) million (credit)
  • Loss after tax: ₹(175.69) million
  • Basic/Diluted EPS: ₹(8.49)
  • From continuing operations: EPS ₹(8.28)
  • From discontinued operations: EPS ₹(0.21)

Management Appointments and Re-appointments

New Appointment:

  • Mr. Shleshank Laheri appointed as Chief Financial Officer and KMP effective August 11, 2026
  • Chartered Accountant with 22 years experience in investment banking, healthcare, and FMCG sectors
  • Previously worked with Kotak Group, Deutsche Capital Market, Citi Group, UnitedHealth Group, Reliance Retail, and Graviss Group

Re-appointments (subject to shareholder approval):

  • Mr. Prayas Goel (DIN: 003485219) as Managing Director for 3 years from April 1, 2027 to March 31, 2030
  • Mr. Prakash Shah (DIN: 00286277) as Non-Executive Independent Director for second 5-year term from May 25, 2027 to May 24, 2032
  • Ms. Kamal Shanbhag (DIN: 09578441) as Non-Executive Independent Director for second 5-year term from May 25, 2027 to May 24, 2032
  • Mr. Shiraz Bugwadia (DIN: 01213884) as Non-Executive Independent Director for second 5-year term from June 20, 2027 to June 19, 2032

IPO Proceeds Utilization

  • IPO completed on December 27, 2024 raising ₹175.00 crores (net of issue expenses)
  • Total offer expenses: ₹129.24 million
  • No deviation or variation in utilization of IPO proceeds as of June 30, 2026
  • Unutilized amount: ₹432.58 million, of which ₹431.80 million temporarily invested in bank deposits

Detailed Utilization as of June 30, 2026:

  • Investment in CEF for greenfield project: ₹75.35 million utilized of ₹250.00 million allocated
  • Investment in RSSPL for brownfield expansion: ₹0 utilized of ₹105.05 million allocated
  • Purchase of plant and machinery: ₹4.84 million utilized of ₹32.07 million allocated
  • Investment in Concord Enviro FZE for debt repayment: ₹500.00 million utilized of ₹500.00 million allocated
  • Investment in CEF for working capital: ₹0 utilized of ₹200.00 million allocated
  • Investment in Roserve Enviro JV: ₹200.00 million utilized of ₹200.00 million allocated
  • Investment in technology/growth initiatives: ₹0 utilized of ₹100.00 million allocated
  • General corporate purposes: ₹209.54 million utilized of ₹235.00 million allocated
  • Other: ₹198.45 million utilized of ₹198.64 million allocated

Exceptional Items

  • Impact of Labour Codes notified on November 21, 2025: ₹3.90 million recognized in Q4 FY26 (Dec 31, 2025)
  • Provision reversed in Q1 FY27 due to salary framework restructuring
  • Labour Codes include: Code on Wages 2019, Industrial Relations Code 2020, Code on Social Security 2020, Occupational Safety Health and Working Conditions Code 2020

Discontinued Operations

  • Blue Water Trading & Treatment FZE operations discontinued effective February 13, 2025
  • Q1 FY27 loss from discontinued operations: ₹4.33 million
  • Classified as disposal entity and discontinued operation

Board Meeting Details

  • Meeting held on August 11, 2026
  • Commenced at 17:45 IST, concluded at 18:12 IST
  • Authorized directors for materiality determination: Prayas Goel (MD), Prerak Goel (ED), Shleshank Laheri (CFO)

Business Segment

  • Single business segment: water treatment products and technologies
  • Provides water and wastewater treatment and reuse solutions including zero liquid discharge (ZLD) technology

Subsidiaries and Joint Ventures

Consolidated results include:

  • 10 subsidiaries including Rochem Separation Systems, Concord Enviro FZE, Blue Water Trading & Treatment FZE
  • 4 joint ventures including Roserve Enviro Private Limited
  • 9 subsidiaries not reviewed by statutory auditors, representing revenues of ₹389.64 million and loss after tax of ₹107.56 million for Q1 FY27